

This item is the archived peer-reviewed author-version of:

Antibiotic prescribing for acute respiratory tract infections 12 months after communication and CRP training : a randomized trial

Reference:

Little Paul, Stuart Beth, Francis Nick, Anthierens Sibyl, Coenen Samuel, Goossens Herman, et al.- Antibiotic prescribing for acute respiratory tract infections 12 months after communication and CRP training : a randomized trial
Annals of Family Medicine online - ISSN 1544-1709 - 17:2(2019), p. 125-132
Full text (Publisher's DOI): <https://doi.org/10.1370/AFM.2356>
To cite this reference: <https://hdl.handle.net/10067/1579570151162165141>

1 Title: Antibiotic prescribing for acute lower respiratory tract infections (LRTI) 12 months after internet-
2 based training in communication skills and using CRP: a multi-national randomised trial
3

4 Authors: Paul Little, Beth Stuart, Nick Francis, Elaine Douglas, Sarah Tonkin-Crine, Sibyl Anthierens,
5 Jochen W.L. Cals, Hasse Melbye, Miriam Santer, Michael Moore, Samuel Coenen, Chris C. Butler,
6 Kerenza Hood, Mark Kelly, Maciek Godycki-Cwirko, Artur Mierzecki, Antoni Torres, Carl Llor, Melanie
7 Davies, Mark Mullee, Gilly O'Reilly, Alike van der Velden, Adam W.A. Geraghty, Herman Goossens,
8 Theo Verheij, and Lucy Yardley on behalf of the GRACE consortium.
9

10 Professor Paul Little FRCGP, Professor Mark Mullee MSc, Dr Beth Stuart PhD, Dr Gilly O'Reilly PhD and
11 Professor Michael Moore FRCGP, Dr Adam W.A. Geraghty PhD, Professor Miriam Santer PhD, Primary Care and
12 Population Sciences Unit, University of Southampton, UK

13 Professor Lucy Yardley PhD, and Ms Elaine Douglas, MSc, Department of Psychology, University of Southampton,
14 UK and Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

15 Professor Theo J. Verheij, PhD MRCGP and Dr Alike van der Velden PhD, Julius Center for Health Sciences and
16 Primary Care, University Medical Center Utrecht, the Netherlands.

17 Professor Christopher C Butler FRCGP, Dr Sarah Tonkin-Crine PhD, Nuffield Department of Primary Care Health
18 Sciences, University of Oxford, UK

19 Professor Nick Francis PhD, Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, UK.

20 Professor Kerenza Hood PhD, and Mr Mark Kelly PhD, South East Wales Trials Unit, Centre for Trials Research,
21 Cardiff University

22 Professor Maciek Godycki-Cwirko MD Ph Hab. , Centre for Family and Community Medicine, Faculty of Health
23 Sciences, Medical University of Łódź, Poland.

24 Associate Professor Artur Mierzecki, PhD Laboratory of Family Physician Education, Pomeranian Medical
25 University in Szczecin, Poland.

26 Ms Mel Davies BSc Research Manager, Ely Bridge Surgery, Ely, Cardiff, UK.

27 Professor Antoni Torres, PhD Pneumology Department, Clinic Institute of Thorax (ICT), Hospital Clinic of
28 Barcelona- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)- University of Barcelona (UB)-
29 Ciber de Enfermedades Respiratorias (Ciberes) Villarroel 170, 08036 Barcelona, Spain.

30 Professor Samuel Coenen, PhD, Department of Primary and Interdisciplinary Care (ELIZA), Vaccine & Infectious
31 Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.

32 Professor Herman Goossens, PhD, Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute
33 (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.

34 Dr Sibyl Anthierens, PhD Department of Primary and Interdisciplinary Care (ELIZA), University of Antwerp,
35 Belgium

36 Dr Carl Llor, PhD University Rovira i Virgili, Tarragona, Spain. Spanish Society of Family Medicine (semFYC).

37 Dr Jochen W.L. Cals, Maastricht University/CAPHRI, Maastricht, The Netherlands

38 Professor Hasse Melbye, **PhD**, University of Tromso, Norway
39 Word count 2374. Correspondence to Professor Little p.little@soton.ac.uk Tel +44 23 8059 1759 ; fax +44
40 2361 701125. University of Southampton. Aldermoor Health Centre, Aldermoor close, Southampton UK.
41 SO16 5ST.
42

43 **Abstract**

44 **Purpose.** C-Reactive-Protein(CRP) has diagnostic utility for lower Respiratory infections (LRTI). A large
45 international trial documented that training in communication skills, CRP, or both, reduced antibiotic
46 prescribing at 3 months (risk ratios 0.68,0.53,0.38 respectively). We report the longer term impact.

47 **Methods.** 246 general practices in 6 countries were cluster-randomised using computer-generated random
48 numbers to:

49 1) Usual care (n=61); Internet training for 2) CRP point-of-care-test (POCT) (n=62), or 3) enhanced
50 communication skills and interactive booklet (n=61), or 4) combined interventions (n=62). Outcome:
51 antibiotic prescribing audited for RTIs after 12 months(12m).

52 **Results.** Of 228 practices providing 3m data 168 (74%) provided 12m data (n=40,39,41,48 respectively)
53 with no demonstrable attrition bias. Prescribing had reduced in usual care (3m 58%(508/870); 12m
54 51%(613/1194)), but increased for the CRP (3m 35%(368/1062), 12m 43%(456/1052); adjusted RR (Risk
55 Ratio) compared to usual care 0.75 (95% CIs 0.51,1.00), p=0.052) and combined groups (3m
56 32%(476/1170), 12m 45% (641/1410), RR 0.70 (0.49,0.93), p=0.013). However, reductions for
57 communication training were maintained (3m 41%(476/1170), 12m 40%(465/1166), RR 12m 0.70
58 (0.49,0.94), p=0.017). Despite being freely provided, CRP POCT was hardly used at 12m, and booklets
59 used sparingly. Enhanced communication, but not CRP, remained effective for Lower RTIs (RRs 0.71,
60 0.45 to 0.99; and 0.76, 0.47 to 1.06) respectively), whereas both remained effective for Upper RTIs (0.60;
61 0.37 to 0.94 p=0.023; 0.58 0.36 to 0.92; 0.018).

62 **Conclusion.** Internet-based training in enhanced communication skills remains effective in the longer
63 term. The effect of CRP training wanes and becomes ineffective for LRTI, the only current indication for
64 using CRP.

65

66 Funding: EuropeanCommissionFrameworkProgramme6; UK NIHR; ResearchFoundation–

67 Flanders(G.0274.08N); European Science Foundation; **Trial Registration:**ISRCTN99871214

68

69 **Introduction**

70 Acute uncomplicated lower (LRTI) and upper (URTI) respiratory tract infections are the most common
71 acute presentations in primary care, and most patients still receive antibiotics^{1 2 3 4} despite evidence of
72 limited benefit^{5 4 6}. Antibiotic resistance is a major threat and primary care prescribing has a key role⁷.

73

74 Educational outreach and training in enhanced communication skills for physicians to explore patients'
75 concerns can reduce antibiotic prescribing⁸⁻¹³. Particular concerns for physicians and patients are
76 complications such as pneumonia^{14 15} where LRTI C-Reaction-Protein (CRP) point-of-care-tests (POCT)
77 have diagnostic utility¹⁶. Physician training for CRP POCTs reduces antibiotic prescribing by
78 approximately 20%^{8 9} in the short term, so several guidelines now advocate CRP (e.g. European
79 Respiratory Society(ERS); European Society Clinical Microbiology and Infectious Diseases(ESCMID);
80 National Institute for Health and Care Excellence (NICE))^{17 18 19}.

81

82 Evidence for educational outreach mostly documents highly expert teams helping a small numbers of
83 practices i.e. of limited generalisability. However, a large pan-European trial documented the impact of
84 brief internet-based physician training by: 1) using a CRP POCT and; 2) enhanced communication skills
85 and using an interactive patient booklet. **There was a clinically unimportant increase of one day of**
86 **symptoms (a secondary outcome, documented in a symptom diary)²⁰, but both interventions reduced**
87 **antibiotic prescribing (the primary outcome)** by 3 months (risk ratio (RR) 0.53 and 0.68 respectively;
88 combined intervention 0.38)²⁰. It is unclear if either of these brief interventions has longer lasting effects
89 on antibiotic use - which is vital to curb the danger of antibiotic resistance. We report the impact of the
90 interventions after 12 months.

91

92 **Methods**

93 The methods of this trial are given in greater detail elsewhere²⁰. A summary is included below.

94 **Rationale of trial design**

95 A cluster design was chosen to minimise contamination within practices.

96 **Changes following trial commencement**

97 Funding uncertainty meant asking participating physicians for the 12 month audit only after completing
98 the 3 month audit. Clinical outcomes were not documented at 12 months – due to resource limitations
99 and also minimal impact at 3 months¹⁶. At 3 months there were no significant differences between
100 groups in hospital admissions (2 control; 10 CRP; 6 Communication; 12 Combined - mostly cardio-
101 respiratory, or systemic upset (e.g. high fever)).

102 **Participating networks, physician practices, and audits**

103 Eight primary care research networks invited local physician practices. Networks covered a range of
104 health systems, languages and cultures: England (Southampton); Wales (Cardiff); Netherlands (Utrecht);
105 Belgium (Antwerp); Poland (Łódź; Szczecin); and Spain (Barcelona; the SemFYC network).. Within
106 each practice, all who prescribed antibiotics for RTI could participate (including some UK nurse
107 prescribers).

- 108 • Baseline audit of consecutive participants to document usual prescribing : October -December
109 2010
- 110 • 3 month audit²⁰: February -May 2011; physicians were asked to recruit 30 consecutive patients
111 with LRTI (the main intervention target) and 5 URTIs.
- 112 • 12 month audit: October 2011-May 2012; since the interventions were effective for both
113 LRTI/URTI at 3 months²⁰, both LRTI and URTI were included with no instructions to
114 preferentially recruit LRTI.

115 **Inclusion criteria for practices:** no prior participation in antibiotic stewardship interventions; able to
116 recruit 10+ patients at baseline.

117 **Patients**

118 **Inclusion criteria.** Adults (≥ 18 years old) with:

119 **LRTI:** ≤ 28 days of cough as the most prominent symptom, or if not (e.g. chills prominent) the
120 clinician judged LRTI was the diagnosis. Pneumonia and chronic airways disease were included
121 since their management could have been modified by the interventions.

122 **URTI:** judged by the clinician to be another RTI (sore throat, otitis media, sinusitis, influenza
123 and/or coryzal illness).

124 **Exclusions:** non-infective diagnosis (e.g. pulmonary embolus); recent antibiotic (28 days);
125 informed consent impossible (e.g. dementia); pregnancy; immune deficiencies.

126 **Case report form (CRF):** clinicians documented symptoms and signs, illness duration, the use of: CRP
127 booklets, and antibiotic prescribing.

128 **Randomisation**

129 Remote randomisation of practices used minimisation based on practice characteristics (baseline
130 prescribing; number of physicians; number of patients at baseline), stratified by network.

131 **Intervention**

132 The two interventions (enhanced communication; CRP) were developed to be sensitive to cultural
133 differences²¹ whilst retaining core features. Practices were randomised to one of four trial arms:

- 134 1. **Usual care.** No intervention provided.
- 135 2. **CRP: Internet training to use a CRP POCT.** The POCT device was demonstrated by company
136 representatives; internet training provided guidance on targeting CRP use (Appendix 1). The device
137 and testing materials were provided free.
- 138 3. **Internet based training in enhanced communication skills and using an interactive patient**
139 **booklet** (see Appendix 1). The internet training focused on interactive use of a booklet in
140 consultations and enhanced patient-centred communication - eliciting concerns/expectations,
141 information exchange, agreeing management, summing up, and safety netting – supported by short
142 demonstration video clips. The booklets included information about the cause of symptoms; natural

143 history; antibiotics; self-help and when to re-consult. Group practices appointed a lead physician to
144 organise a structured meeting on prescribing.

145 4. **Combined intervention.** Physicians received both training interventions.

146 **Outcomes**

147 Primary outcome: antibiotic prescribing documented in the CRF by the recruiting clinician. There was no
148 individual level consent for data collection at 12 months. Limited availability of prescription monitoring
149 prevented pharmacy dispensing data being used.

150

151 **Sample size calculation (for alpha 0.025; beta 0.2)**

152 We assumed: 30 patients/practice would be recruited; antibiotic prescribing reductions of 50% to 40%
153 for either intervention^{8 22}; an intra-cluster coefficient (ICC) from 0.16 (^{8 23 24}) to 0.06²⁵. Hence we
154 required 2600 (ICC 0.06) to 5400 patients (ICC 0.16).

155 **Analysis**

156 Multilevel logistic regression modelling for a factorial study was used, controlling for baseline antibiotic
157 prescribing rate, clustering by physician and practice, whether a URTI or LRTI, and a range of potential
158 confounders (see bottom of Tables 2,3). There was no additional effect of international network hence it
159 was not included in models. A secondary analysis reported individual randomisation groups since the
160 study was not powered for interactions. The odds ratios were converted to risk ratios (Zhang et al²⁶). The
161 analysis was intention-to-treat. To assess attrition bias we performed two analyses: 1) using data
162 aggregated at the practice level, and using multiple imputation to impute data from practices who had not
163 agreed to be followed-up 2) comparison of estimates at 3 months just for those practices followed up at 12
164 months.

165

166 **Results**

167 At the baseline audit 5355 patients (79.1%) had LRTI, and 1416 (20.9%) URTI, of whom 3742 (55%)
168 were prescribed antibiotics. 372 participating physicians in 228 of 246 practices contributed 4264 patients
169 at the 3 month follow-up (see Figure1) of whom 20% had URTI. Of 228 practices providing 3 month
170 data 168 (74%) provided 12 month data. 247 physicians in the 168 practices contributed 4830 patients at
171 the 12 month follow-up and 41% of patients had URTI, hence URTI was controlled for in the estimates.
172 Groups were well balanced and remained so (Table 1). Initial compliance with training was good, with
173 high completion of all modules (CRP 99/113 (88%); Communication 94/108(87%); Combined 116/127
174 (91%)).

175 By 12 months CRP was little used despite free access to CRP diagnostic kits: Usual care16/1195 (1.34%),
176 CRP 62/1075 (5.77%) Communication 56/1168 (4.79%), Combined 85/1419 (5.99%). Booklets were
177 used more sparingly too: Communication 189/1186 (16%); Combined 340/1428 (24%).

178 **Main findings (Tables 2 and 3)**

179 **Factorial analysis.**

180 At 3 months 48% (984/2040) of participants consulting physicians who were not trained in using CRP
181 were prescribed antibiotics and by 12 months 46% (1078/2360). At 3 months antibiotic prescription in the
182 CRP groups was 33% (734/2224) but by 12 months it was 45% (1097/2462); adjusted risk ratio 0.87
183 compared to control (95% confidence intervals 0.68 to 1.06, p=0.181). At 3 months 45% (876/1932) of
184 participants not in Communication skills groups had antibiotics prescribed, and similar at 12 months
185 (48% (1069/2246). At 3 months 36% (842/2332) of participants in the Communication skills groups had
186 antibiotics prescribed and at 12 months 43% (1106/2576; adjusted risk ratio compared with control 0.81,
187 0.64 to 1.00, p=0.049).

188 **Analysis of individual groups**

189 The factorial analysis probably masks the effectiveness of individual interventions, since there was a
190 sizeable interaction term (1.67;p=0.155) between CRP and Communication interventions. The individual
191 group results at 12 months are shown in Table 3. In those receiving usual care (i.e. no training) 58%

192 (508/870) were prescribed antibiotics at 3 months, and this had reduced by 7% to 51% (613/1194) at 12
193 months in part due to more URTI. However for CRP training figures reversed 35% (368/1062) at 3
194 months, rising by 9% to 43% (456/1052) at 12 months (adjusted risk ratio compared to usual care at 12
195 months 0.75, 0.51 to 1.00, $p=0.052$). Similarly for the combined group: 32% (476/1170) were prescribed
196 antibiotics at 3 months, rising by 13% to 45% (641/1410) at 12 months (adjusted risk ratio compared to
197 usual care at 12 months 0.70, 0.49 to 0.93, $p=0.013$). In contrast for Communication skills 41%
198 (476/1170) were prescribed antibiotics at 3 months, and maintained by 12 months (40%, adjusted risk
199 ratio compared to usual care 0.70, 0.49 to 0.94, $p=0.017$). Enhanced communication was also still
200 effective for LRTI (adjusted risk ratio 0.71, 0.45 to 0.99) but CRP was not (0.76, 0.47 to 1.06) whereas
201 both interventions maintained an effect on URTI. (respectively 0.60; 0.37 to 0.94 $p=0.023$; 0.58 0.36 to
202 0.92; 0.018).

203 **Attrition bias**

204 Data from practices where follow-up was possible was comparable to the overall trial cohort (see
205 Appendix 2 tables 5 and 6). The practice level analysis compared the results of the ‘completers’ analysis
206 (from practices that agreed to follow-up) with the estimates based on including all practices in an imputed
207 data set. Although the absolute estimates of effectiveness were slightly different with lower power and
208 were less robust (due to the inability to control for individual patient characteristics), nevertheless no
209 meaningful change in the practice-based estimates occurred when data from the missing practices was
210 imputed. This suggests that minimal attrition bias operated due to practices not agreeing to the follow-up
211 study (Table 4). As a further check the estimates at 3 months from just those practices who were
212 followed-up at 12 months (‘completers’) were very similar to the whole trial cohort (3 months data for the
213 12 month ‘completer’ practices: CRP 0.54, communication training 0.68; full cohort: 0.54, 0.69
214 respectively).

215

216 **Discussion**

217 As far as we are aware, this is the first major multi-centre international trial to assess the longer term
218 effectiveness of internet training to modify antibiotic prescribing for RTIs. Despite a reduction in
219 antibiotic prescribing in usual care, communication training maintained effectiveness, but CRP training
220 did not.

221 **Potential Limitations**

222 Practices were only approached after 3 months to request further follow-up, and 30% of practices
223 declined. However, the baseline characteristics were similar in practices that were not followed up, and
224 the practice-level analysis using multiple imputation demonstrated no attrition bias. Most practices
225 approached agreed, many of whom had not previously taken part in research. As expected clinicians
226 reported struggling to document consecutive patients at busy times of year, but previous research has
227 shown this results in minimal selection bias^{27 28}; there were also minimal barriers to participation for the
228 follow-up (quick audit proformas; no delay for patient consent), there was no evidence of differential
229 selection bias comparing groups, and analysis controlled for any differences in case mix. Furthermore,
230 antibiotic prescribing was similar to previous studies^{4 2}, and most patients at baseline in usual care
231 received antibiotics, which suggests generalisable results. At 12 months usual care prescribing reduced
232 slightly by 6% - perhaps due to pressure on physicians (e.g. the European Antibiotic Awareness Day),
233 but also there were more patients with URTI (which explained half the reduction). However the findings
234 cannot be explained by case mix since we controlled for a range of variables in the analysis. We checked
235 fidelity with initial training but didn't observe consultations (to avoid changing behaviour). We did not
236 record clinical outcomes since given the modest impact initially²⁰.

237 **Comparison with other studies**

238 Interactive communication was effective in the longer term, supporting prior evidence for interactive
239 methods^{10 11}. Our process studies also indicated that the communication intervention promoted changes in
240 physician attitudes that should be helpful in the longer-term^{21 29 30}. STAR achieved a 4% reduction in
241 global antibiotics but was more intensive (five online phases vs one in this study; expert-led outreach

242 seminars)¹³. Our intervention caused less initial reduction than the Dutch IMPAC3T trial⁸, but IMPAC3T
243 was also more intensive, with face-to-face communication training. The long-term effect on behaviour in
244 the current study was similar to other more intensive interventions^{8 13 31}. Booklets were initially important,
245 but their limited use in follow-up - despite the intervention maintaining effectiveness - suggests that
246 doctors had consolidated skills and were being more selective.

247
248 Communication skills-training was less slightly effective than using CRP, or the combined intervention
249 at 3 months (risk ratios 0.68,0.53,0.38 respectively), comparable to the Dutch trials^{8 9}. However, despite
250 providing all materials free, CRP tests were little used by 12 months, and the effectiveness of CRP had
251 waned substantially (0.70,0.75, 0.70 respectively) – but the reduced impact was particularly for LRTI
252 where CRP is supported^{17 18 19}. Our findings support the long term findings for LRTI from the smaller
253 intensive IMPAC3T trial, where there was no longer a significant effect of CRP training but the effect of
254 communication training remained³¹. The waning in effectiveness of CRP may reflect the waning of
255 quality improvement interventions with time, and it is unclear if further reduction in effectiveness would
256 happen beyond 12 months. The logistics of providing CRP, and time taken to do CRP at the busiest times
257 of year may be key disincentives to longer term engagement. The ongoing impact of CRP training for
258 URTI despite low use of CRP may reflect physicians having learnt to prescribe fewer antibiotics when
259 using CRP, or that both CRP and Communication training shared introductory modules about the limited
260 benefit of antibiotics i.e. a non-specific effect not related to CRP per se. Ongoing incentives would
261 probably be needed for physicians to continue using CRP, but evidence of cost-effectiveness of this
262 approach would be needed.

263 **Conclusion**

264 Internet-based training in enhanced communication skills remains effective in the longer term. The effect
265 of CRP training wanes and becomes ineffective for LRTI, the only current indication for using CRP. In
266 routine clinical practice there is only likely to be short term benefit from training GPs to use CRP. The
267 most useful training for long lasting effects is in enhanced communication skills.

268

269

270 **Acknowledgements and Contributorship.**

271 The research performed by the GRACE (Genomics to combat Resistance against Antibiotics in Community-
272 acquired LRTI in Europe) consortium leading to these results was funded by the European Community's Sixth
273 Framework Programme under grant agreement no. 518226. The work in UK was also supported by the National
274 Institute for Health Research (service support costs), and the Research Foundation –Flanders (G.0274.08N). The
275 funders and sponsor (University of Southampton) had no role in the management, analysis, interpretation nor write-
276 up of this project. We are grateful to Orion Diagnostica for supplying all the equipment and consumables for CRP
277 testing.

278 The work reported as part of the final follow-up was also supported through the European Science Foundation
279 (ESF), in the framework of the Research Networking Programme TRACE (www.esf.org/trace) (whose contributors
280 were *Bond University (Australia), Research Foundation – Flanders, University of Antwerp, University of Ghent*
281 *(Belgium), Chinese University of Hong Kong (China), University of Copenhagen (Denmark), Research Council of*
282 *Health, Academy of Finland (Finland), Collège Azuréen des Généralistes Enseignants, Comité Départemental*
283 *d'Éducation pour la Santé (France), Rostock University (Germany), The Netherlands Organisation for Scientific*
284 *Research, AMC Amsterdam, Leiden UMC, UMC Utrecht (The Netherlands), Research Council of Norway,*
285 *University of Oslo, University of Tromsø (Norway), Medical University of Białystok, Medical University of Łódź*
286 *(Poland), National University Research Council (Romania), Osnovno zdravstvo Gorenjske (Slovenia), l'Institut*
287 *d'Investigacions Biomèdiques August Pi i Sunyer (Spain), Swedish Research Council, Karolinska Institute (Sweden),*
288 *Medical Research Council, Cardiff University, University of Oxford, University of Southampton (United Kingdom),*
289 *Swiss National Science Foundation (Switzerland)).*

290 The initial idea for this study was proposed by PL, TV, CCB, SC and HG; all authors contributed to the
291 development of the protocol, and to the management of the study; Gilly O'Reilly and Curt Brugman led the day to
292 day management of the study supervised by PL and TV respectively; LY led and supervised the design and
293 development of the web-based intervention; LY, NF, PL, CCB led the development of the communication
294 intervention. JC, HM and PL led the development of the CRP intervention. Both interventions benefited from input
295 of the network leads. Frank Leus supervised the web based data management. HG led the funding application and
296 provided overall coordination of the GRACE consortium; KH coordinated randomisation and MK; PL, BS and
297 MMu analysed the data; all authors contributed to the interpretation of the data and the write up. PL, MMu and BS
298 had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of
299 the data analysis. No authors have a conflict of interest.

300 We are grateful to Zoe Crosby and Ian Williamson (who have provided helpful support during the study, and were
301 part of protocol development in discussion with PL). Key members of the GRACE consortium trial team whose hard
302 work has made this possible are: Niels Adriaenssens, Zuzana Bielicka, Pascale Bruno, Jo Coast, Patricia Fernandez,
303 Iris Hering, Anna Kowalczyk, Christina Lannering, Marieke Lemiengre, Katherine Loens, Christine Lammens,
304 Greet Ieven , Bo-Eric Malmvall, Anna Kowalczyk, Jaroslaw Krawczyk , Nuria Sanchez Romano, Matteu Serra Prat,

305 Igor Svab, Richard Smith, Jackie Swain, Francesco Blasi, Ann de Sutter, Pia Touboul, Tom Schaberg, Sigvard
306 Molstad, Paolo Tarsia, Helena Hupkova, Janko Kersnik, Frank Leus, Robert Veen, Tricia Worby, Ana Moragas,
307 Josep Maria Cots, Javier Arranz, Guillermo García, Gloria Rabanaque, and Juande Alcántara.. We are very grateful
308 to all the clinicians and patients who consented to be part of GRACE, without whom this study would simply not
309 have been possible. We would also like to thank the independent GRACE trial steering committee for their help and
310 suggestions (Patrick Bindels, Gordon Taylor, and Mark Woodhead). The trial steering committee also supervised
311 safety aspects of the trial since there was no independent data safety monitoring board (following similar precedents
312 with low risk MRC funded trials, as the study was considered to be low risk).

313
314
315

316 **Approvals.**

317 Ethical approval for the UK was granted by Southampton and South West Hampshire Local Research Ethics
318 Committee for: Genomics to combat Resistance against Antibiotics for Community acquired lower respiratory tract
319 infection (LRTI) in Europe: INternet Training for Reducing antibiOtic use trial (Short title: GRACE INTRO Trial
320 REC Ref 10/H0502/29). The research sites outside of the UK also obtained ethical approval from their local
321 organisations. Patients who fulfilled the inclusion criteria were given written and verbal information about the study
322 and asked for informed consent.

323 **Funder/author role.**

324 The funders had no role in study management, analysis, write-up or the decision to publish. The PI (PL) made the
325 decision to submit for publication following agreement from all authors.

326
327

329

330 1. Akkerman E, Van der Wouden J, Kuyvenhoven M, et al. Antibiotic prescribing for respiratory
331 tract infections in Dutch primary care in relation to patient age and clinical entities.

332 *Journal of Antimicrobial chemotherapy* 2004;54:1116-21.

333 2. Petersen I, Johnson A, Islam A, et al. Protective effect of antibiotics against serious
334 complications of common respiratory tract infections: retrospective cohort study with the
335 UK General Practice Research Database. *BMJ* 2007;335:982 (10 November),
336 doi:10.1136/bmj.39345.405243.BE.

337 3. Kroening-Roche J, Soroudi A, Castillo E, et al. Antibiotic and bronchodilator prescribing for
338 acute bronchitis in the emergency department. *J Emerg Med* 2012;43:221-27.

339 4. Butler C, Hood K, Verheij T, et al. Variation in antibiotic prescribing and its impact on
340 recovery in patients with acute cough in primary care: prospective study in 13 countries.
341 *BMJ* 2009;b2242

342 5. Smith S, Fahey T, Smucny J, et al. Antibiotics for acute bronchitis. *Cochrane Library*
343 2014;DOI: 10.1002/14651858.CD000245.pub3

344 6. Little P, Stuart B, Moore M, et al. Amoxicillin for acute lower respiratory tract infection
345 where pneumonia is not suspected clinically : a 12 country randomised placebo
346 controlled trial in primary care. *Lancet Infectious Disease* 2013;Feb;13(2):123-9. doi:
347 10.1016/S1473-3099(12)70300-6.

348 7. Goossens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and
349 association with resistance: a cross-national database study. *Lancet* 2005;365:579-87.

350 8. Cals J, Butler C, Hopstaken R, et al. Effect of point of care testing for C reactive protein and
351 training in communication skills on antibiotic use in lower respiratory tract infections:
352 cluster randomised trial. *BMJ* 2009;doi:10.1136/bmj.b1374

353 9. Cals J, Schot M, de Jong S, et al. Point-of-care C-reactive protein testing and antibiotic
354 prescribing for respiratory tract infections: a randomized controlled trial. *Ann Fam Med*
355 2010;8(124):133.

356 10. Arnold S, Straus S. Interventions to improve antibiotic prescribing practices in ambulatory
357 care. *Cochrane Database of systematic reviews* 2005

358 11. O'Brien M, Rogers S, Jamtvendt G, et al. Educational outreach visits: effects on professional
359 practice and health care outcomes. *Cochrane Database of systematic reviews* 2007

360 12. van der Velden A, Pijpers E, Kuyvenhoven M, et al. Effectiveness of physician-targeted
361 interventions to improve antibiotic use for respiratory tract infections. *BJGP*
362 2012;62:e801-e07(7).

363 13. Butler C, Simpson S, Dunstan F, et al. Effectiveness of multifaceted educational programme
364 to reduce antibiotic dispensing in primary care: practice based randomised controlled
365 trial. *BMJ* 2012;344:d8173. doi: 10.1136/bmj.d8173.

366 14. Kumar S, Little P, Britten N. Why do Gps prescribe antibiotics for sore throat? A grounded
367 theory interview study of general practitioners. *BMJ* 2003;326:(18 January):138.

368 15. Cornford CS. Why patients consult when they cough: a comparison of consulting and non-
369 consulting patients. *BJGP* 1998;48:1751-54.

370 16. Minnaard MC, de Groot JA, Hopstaken RM, et al. The added value of C-reactive protein
371 measurement in diagnosing pneumonia in primary care: a meta-analysis of individual
372 patient data. *Cmaj* 2016 doi: 10.1503/cmaj.151163 [published Online First: 2016/09/21]

373 17. NICE clinical guideline 191: Pneumonia Diagnosis and management of community- and

- 374 hospital-acquired pneumonia in adults. *NICE* 2014;191
- 375 18. Verheij T, Hopstaken R, Prins Jea. NHG-Standaard Acute hoesten. [Dutch College of
376 General Practitioners Guidelines on Acute Cough 2011, updated 2013]. *Huisarts Wet*
377 2011;54:68-92.
- 378 19. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower
379 respiratory tract infections--full version. *Clin Microbiol Infect* 2011;17 Suppl 6:E1-E59.
- 380 20. Little P, Stuart B, Francis N, et al. Effects of internet-based training on antibiotic prescribing
381 rates for acute respiratory-tract infections: a multinational, cluster, randomised, factorial,
382 controlled trial. *Lancet* 2013;doi:10.1016/S0140-6736(13)60994-0
- 383 21. Anthierens S, Tonkin-Crine S, Douglas E, et al. General practitioners' views on the
384 acceptability and applicability of a web-based intervention to reduce antibiotic prescribing
385 for acute cough in
386 multiple European countries: a qualitative study prior to a randomised trial. *BMC Fam Pract*
387 2012;13:101:doi:10.1186/471-2296-13-101.
- 388 22. Francis N, Butler C, Hood K, et al. Effect of using an interactive booklet about childhood
389 respiratory tract infections in primary care consultations on reconsulting and antibiotic
390 prescribing: a cluster randomised controlled trial. *BMJ* 2009;339:b2885.
- 391 23. Coenen S, Van Royen P, Michiels B, et al. Optimizing antibiotic prescribing for acute cough
392 in general practice: a cluster-randomized controlled trial. *J A C* 2004;54(3):661
393 (doi:10.1093/jac/dkh374)-672.
- 394 24. Welschen I, Kuyvenhoven M, Hoes A, et al. Effectiveness of a multiple intervention to
395 reduce antibiotic prescribing for respiratory tract symptoms in primary care: randomised
396 controlled trial. *BMJ* 2004;329:431 (21 August), doi:10.1136/bmj.38182.591238.EB.
- 397 25. Adams G, Gulliford M, Ukoumunne O, et al. Patterns of intra-cluster correlation from
398 primary care research to inform study design and analysis. *J Clin Epidemiol* 2004
399 Aug;57(8):785-94 2004;57:785-94.
- 400 26. Zhang J, Yu K. What's the relative risk? A method of correcting the odds ratio in cohort
401 studies of common outcomes. *JAMA* 1998;280:1690-91.
- 402 27. Little PS, Williamson I, Warner G, et al. An open randomised trial of prescribing strategies
403 for sore throat. *B M J* 1997;314:722-27.
- 404 28. Little P, Gould C, Williamson I, et al. A pragmatic randomised controlled trial of two
405 prescribing strategies for acute otitis media. *BMJ* 2001;322:336-42.
- 406 29. Yardley L, Douglas E, Anthierens S, et al. Evaluation of a web-based intervention to reduce
407 antibiotic prescribing for LRTI in six European countries: quantitative process analysis of
408 the GRACE/INTRO randomised controlled trial. *Implementation Science*
409 2013;8:134:doi:10.1186/748-5908-8-134.
- 410 30. Anthierens S, Tonkin-Crine S, Cals J, et al. Clinicians' Views and Experiences of
411 Interventions to Enhance the Quality of Antibiotic Prescribing for Acute Respiratory
412 Tract Infections. *JGIM* 2014;DOI 10.1007/s11606-014-3076-6
- 413 31. Cals J, De Bock L, Beckers P-J, et al. Enhanced Communication Skills and C-reactive
414 Protein Point-of-Care Testing for Respiratory Tract Infection: 3.5-year Followup of a
415 Cluster Randomized Trial. *Ann Fam Med* 2013;11 doi:10.1370/afm.1477.:157-64.
- 416 32. Yardley L, Joseph J, Michie S, et al. Evaluation of a Web-based intervention providing
417 tailored advice for self-management of minor respiratory symptoms: exploratory
418 randomized controlled trial. *J Med Internet Res* 2010;12:e66.

- 419 33. van der Meer V, Neven AK, van den Broek PJ, et al. Diagnostic value of C reactive protein
420 in infections of the lower respiratory tract: systematic review. *BMJ* 2005;331:26.
421 34. Falk G, Fahey T. C-reactive protein and community-acquired pneumonia in ambulatory care:
422 systematic review of diagnostic accuracy studies. *Fam Pract* 2009;26:10-21.
423
424

425 Table 1 – Patient characteristics (n (%) or mean (SD))

	Final twelve months follow up				Initial three months follow-up period				Baseline
	Control for CRP	CRP	Control for comm'n	Communic'n	Control for CRP	CRP	Control for communic'n	Communicat'n	
Gender (female)	1,470/2,463 (60%)	1,620/2,699 (60%)	1,466/2,464 (60%)	1,624/2,698 (60%)	1311/2040 (64%)	1423/2224 (64%)	1223/1932 (63%)	1511/2332 (65%)	4218/6771 (62%)
Age in years (mean (SD))	51.7 (18.8)	51.2 (18.7)	51.1 (18.6)	51.7 (18.8)	50.9 (17.3)	51.0 (17.5)	50.8 (17.6)	51.1 (17.2)	49.6 (18.6)
Non-smoker (past or current)	N/A	N/A	N/A	N/A	1067/2040 (52%)	1147/2224 (52%)	1041/1932 (54%)	1173/2332 (50%)	N/A
Illness duration prior to the index consultation greater than 5 days	1,026/2,463 (42%)	1,198/2,699 (44%)	1,032/2,464 (42%)	1,192/2,698 (44%)	1038/2027 (51%)	1128/2209 (51%)	994/1917 (52%)	1172/2319 (51%)	3,542/6717 (53%)
Respiratory rate (greater than 25 breaths/minute)	65/2462 (3%)	133/269 (5%)	96/2464 (4%)	102/2698 (4%)	101/1991 (5%)	123/2142 (6%)	145/1866 (8%)	79/2267 (3%)	N/A
Temperature (greater than 38 degrees C)	291/2463 (12%)	380/2699 (14%)	285/2464 (12%)	386/2698 (14%)	228/2002 (11%)	280/2152 (13%)	202/1853 (11%)	306/2301 (13%)	N/A

426

427

428

429

430

431 Table 2 - Effectiveness of CRP and enhanced-communication training in reducing antibiotic
 432 prescribing rates **at 12 months**

	No CRP training	CRP training	No communication training	Communication training
Crude percentage	45.7% (1,078/ 2,360)	44.6% (1,097/ 2,462)	47.6% (1,069/ 2,246)	42.9% (1,106/2,576)
Basic risk ratio (95% CI)*	1.00	0.91 (0.77, 1.05;p=0.223)	1.00	0.90 (0.77, 1.04; p=0.170)
Adjusted risk ratio†	1.00	0.87 (0.68, 1.06; p=0.181)	1.00	0.81 (0.64, 1.00; p=0.049)

433 CRP=C-reactive protein. *The basic model adjusted for baseline prescribing and clustering by physician and practice. †The
 434 adjusted model controlled for diagnosis (LRTI, URTI, pneumonia), sex, age, presence of cough, phlegm, shortness of breath,
 435 blocked/runny nose, chest pain, fever, muscle ache, headache, disturbed sleep, feeling generally unwell, interference with social
 436 activities, earache, sore throat, facial/sinus pain, crackles, wheeze, pulse higher than 100 beats per min, temperature higher than
 437 37.8°C, respiratory rate, physician's rating of severity, low blood pressure, duration of cough and duration of illness prior to
 438 consultation.

439 Table 3 - Effectiveness of CRP and enhanced-communication training in reducing antibiotic
 440 prescribing rates **at 12 months**

	Control	CRP	Enhanced communication	Combined
Crude percentage	51.3% (613/1,194)	43.4% (456/1,052)	39.9% (465/1,166)	45.5% (641/1,410)
Basic risk ratio (95% CI)*	1.00	0.83 (0.66, 1.02; p=0.083)	0.83 (0.66, 1.01; p=0.065)	0.83 (0.66, 1.00; p=0.053)
Adjusted risk ratio†	1.00	0.75 (0.51, 1.00; p=0.052)	0.70 (0.49, 0.94; p=0.017)	0.70 (0.49, 0.93; p=0.013)

441 CRP=C-reactive protein. *The basic model adjusted for baseline prescribing and clustering by physician and practice. †The fully
 442 adjusted model controlled for the variables listed above.

443

444 Table 4 - Effectiveness of CRP and enhanced-communication training in reducing antibiotic
 445 prescribing rates based on a practice level analysis compared 'complete case' percentages with
 446 estimates from an imputed dataset **at 12 months**

	Control	CRP	Enhanced communication	Combined
Complete case percentage	51.0%	42.9%	39.8%	47.1%
		-7% (-15, 2; p=0.113)	-7% (-15, 1; p=0.089)	-4 % (-12, 4; p=0.296)
Imputed	Control	CRP	Enhanced communication	Combined
* % receiving antibiotic prescription	49.7%	42.9%	41.9%	47.0%
		-6% (-14, 3; p=0.215)	-7% (-15, 1; p=0.100)	-4% (-12, 4; p=0.342)

447 * Reduction in proportion compared to control controlling for baseline prescribing and practice level averages of patient
 448 characteristics: age, type of infection (LRTI/URTI), presence of symptoms (listed above), crackles, wheeze, pulse higher than
 449 100 beats per min, temperature higher than 37.8°C, respiratory rate, physician's rating of severity, and duration of cough

450

451

452

453 **Appendix 1.**

454

455 **Development of enhanced communication skills and booklet intervention**

456 We developed brief internet based training modules using LifeGuide software, using both prior theory
457 and building on previous interventions: internet training and booklet-based format and content for sharing
458 with patients^{22 32} and the STAR model for communication training¹³. The materials were piloted in every
459 country and modified according to feedback from interviews with physicians and patients in each
460 country²¹. The booklet was endorsed by the European Antibiotic Awareness Day coordinated by the
461 European Centre for Disease Prevention and Control. To reinforce the communication training group
462 practices were asked to appoint a lead physician who organised a structured meeting where prescribing
463 issues were discussed. The experience of using the patient booklet, and recent cases of LRTI were
464 discussed (participants were asked to document presentation, management and their reflection on
465 consultations for up to 10 recent cases). The pragmatic nature of this study required flexibility in
466 arranging meetings: sometimes meetings in practices were not possible (for example with many single
467 handed practices in Belgium, where meetings between practices were encouraged), and sometimes there
468 was strong preference to have centrally organised meetings (e.g. Poland).

469

470 **Development of CRP intervention**

471 The text for guidance on the use of CRP was developed based on systematic review evidence^{33 34} and the
472 previous IMPAC3T trial⁸ and led by Jochen Cals, Hasse Melbye and Paul Little with input from the
473 network leads and collaborators.

474

475 **GRACE INTRO web-based training module**

476 The training modules consisted of up to three sections; an introduction (seen by Communication, CRP,
477 and Combined groups) training in communication skills and use of a patient booklet (seen by
478 Communication and Combined groups) and training in using a C-reactive protein point of care (CRP) test
479 (seen by CRP and Combined groups).

480

481 **1. Introduction**

482 This section presented information describing the problem of antibiotic resistance for healthcare, its
483 relation to antibiotic use, the medicalization of self-limiting illness creating the ‘vicious circle’ of
484 encouraging re-consultation during subsequent episodes, and the difficulties in determining what patients
485 presenting with LRTI in primary care may benefit from antibiotic treatment. The introduction discusses
486 common concerns Physicians have when deciding whether or not to prescribe antibiotics and explains

487 how physician training in communication skills and/or physician use of CRP point of care testing could
488 potentially assist in the consultation.

489


490 **2. Enhanced Communication skills training and use of patient information booklet**

491 The aim of the communication skills training was to facilitate physicians in using specific patient centred
492 communication skills in the acute cough consultation, using three elements of an effective consultation: to
493 gather information about patient beliefs and expectations, exchange information and agree management,
494 and check patient understanding and concordance. Each of these has steps for the physician to follow (see
495 Figure 1 below). The acronym of these seven steps is CHESTTS which helps ease of recollection in the
496 English version of GRACE INTRO.

497

498 Furthermore, it was outlined how a patient booklet could be helpful in the consultation (with a focus on
499 exchanging information and shared decision-making). The web pages presented information, backed by
500 research evidence, to explain how a booklet could help to address patient concerns and maintain patient
501 satisfaction. Physicians were encouraged to make use of tick boxes in the booklet to highlight specific
502 sections which were relevant to individual patients in order to personalise the information. An online
503 discussion forum was also provided for participating physicians but was used by relatively few.

504



505

506 A diagram showing the three elements of an effective consultation and the steps involved in each of these
507 to be carried out by a GP.

508

509 The last section of the communication skills training presented eight short video clips to give examples of
510 how each of the seven tasks above could be achieved in the consultation. For 'Treatment' two videos
511 were displayed; one giving advice about the appropriate use of antibiotics and one video clip giving
512 advice on self-management of acute cough. The video clips were shot in a physician office with a
513 qualified physician giving advice to an actor playing the role of a patient with acute cough. The training
514 ends with a page summarising the key points of communication skills training module.

515

516 **3. C-Reactive Protein (CRP) point of care testing Training**

517 The aim of the training in the use of point of care CRP was to inform physicians about how a point of care
518 CRP result could assist in differentiating self-limiting from serious LRTI and making antibiotic
519 prescribing decisions for LRTI. Physicians were shown how to interpret specific CRP values and how to
520 use the test in their consultations.

521
522 The training starts by giving information on the background of CRP point of care testing and providing
523 evidence to support its use in primary care for LRTI. Physicians were encouraged to use the test to
524 differentiate between serious and self-limiting LRTIs. Common misconceptions were discussed. The
525 module stresses that the test cannot distinguish between viral and bacterial infections in primary care and
526 that it is not a stand-alone test, but should always be used alongside history taking and a physical
527 examination.

528
529 Relevant cut off points were provided (see Table below). As part of dealing with values in the
530 intermediate range (CRP 20-100 mg/l) delayed prescribing was discussed and presented as an option if
531 illness severity combined with CRP did not warrant immediate antibiotics.

532
533 Guidance available to physicians on the cut off points used for CRP values and the relevant treatment
534 options.

535

CRP ≤ 20 mg/l
<ul style="list-style-type: none">▪ Self-limiting LRTI▪ Withhold antibiotics
CRP 21-50 mg/l
<ul style="list-style-type: none">▪ Majority of patients have self-limiting LRTI▪ Assessment of signs, symptoms, risk factors and CRP is important▪ Withhold antibiotics, in most cases
CRP 51-99 mg/l
<ul style="list-style-type: none">▪ Assessment of signs, symptoms, risk factors and CRP is crucial▪ Withhold antibiotics in the majority of cases and consider delayed antibiotics in the minority of cases.
CRP ≥ 100 mg/l
<ul style="list-style-type: none">▪ Severe infection▪ Prescribe antibiotics

536

537 The last section of the CRP training included two short video clips which showed the CRP test procedure,
538 including how to take blood by using a finger prick, running the device and obtaining a result within 4
539 minutes. The training ends with a page summarising the key points of using point of care CRP testing in
540 LRTI in primary care.

541

542

543 **Appendix 2.**

544

545 Table 5.- Characteristics of individual group (n (%) or mean (SD))

	Final twelve months follow-up				Initial three months follow-up period				Baseline
	Control	CRP	Communic'n	Both	Control	CRP	Commun'n	Both	
Gender (female)	730/1244 (59%)	736/1220 (60%)	740/1219 (61%)	884/1479 (60%)	553/870 (64%)	670/1062 (63%)	758/1170 (65%)	753/1162 (65%)	4218/6771 (62%)
Age in years (mean (SD))	50.6 (18.5)	51.8 (18.7)	52.8 (19.0)	50.8 (18.7)	50.5 (17.4)	51.1 (17.7)	51.3 (17.1)	50.9 (17.2)	49.6 (18.6)
Illness duration prior to the index consultation greater than 5 days	512/1244 (41%)	520/1220 (43%)	514/1219 (42%)	678/1479 (46%)	424/863 (49%)	570/1054 (54%)	614/1164 (53%)	558/1155 (48%)	3,542/6717 (53%)
Respiratory rate (> 25 breaths/min.)	39/1244 (3%)	57/1220 (5%)	26/1218 (2%)	76/1479 (5%)	63/846 (7%)	82/1020 (8%)	38/1030 (3%)	41/1145 (4%)	N/A
Temperature (higher than 38 degrees C)	165/1244 (13%)	120/1220 (10%)	126/1219 (10%)	260/1479 (18%)	96/849 (11%)	106/1004 (11%)	132/1153 (11%)	174/1148 (15%)	N/A

546

547

548

549

550 Table 6 - Comparison of characteristics of patients and antibiotic prescribing from practices which provided
 551 follow-up compared with overall cohort (n (%) or mean (SD))
 552

	Final twelve months follow up	Initial three months follow up in those who provided twelve months follow up data	Initial three months follow up	Baseline
Gender (female)	2,891/4830 (59.8%)	2,112/3280 (64.39%)	2,734/4264 (64.1%)	4218/6771 (62%)
Age in years (mean (SD))	51.6 (18.8)	51.1 (17.6)	51.0 (17.4)	49.6 (18.6)
Non-smoker (past or current)	N/A	2561/3280 (78.1%)	3340/4264 (78.3%)	N/A
Illness duration prior to the index consultation greater than 5 days	2,097/4830 (43.4%)	1,649/3265 (50.5%)	2,166/4236 (51.1%)	3,542/6717 (53%)
Respiratory rate (greater than 25 breaths/minute)	178/4830 (3.7%)	184/3190 (5.8%)	224/4122 (5.42%)	N/A
Temperature (greater than 38 degrees C)	639/4830 (13.2%)	408/3235 (12.6%)	508/4154 (12.2%)	N/A
Sputum production	N/A	2631/3271 (80.4%)	3,448/4249 (81.2%)	5355/6771 (79%)
Percentage prescribed antibiotics at baseline	53.7%	55.5%	55.6%	55.3%

553
554

555
556
557
558
559

560 **Appendix 3.**

561

562 **Factorial and Individual group results for LRTI and URTI subgroups**

563 There was no significant difference between patients with LRTI and URTI (interaction term for antibiotic
 564 prescribing between RTI and CRP group 1.15 (p=0.569), and 1.51 (p=0.851) between RTI type and
 565 communication group) but since the power to assess interactions was limited the individual results for
 566 LRTI and other RTIs are shown below.

567

568 **LRTI/URTI Factorial analysis**

569

		Control for CRP	CRP		Control for Communication	Communication
LRTI						
Antibiotics Prescribed	Crude percentage	672/1293 (51.97%)	728/1424 (51.12%)		673/1217 (55.30%)	727/1500 (48.50%)
	Basic risk ratio	1.00	0.97 (0.89, 1.05; p=0.439)		1.00	0.94 (0.86, 1.00; p=0.074)
	Adjusted risk ratio	1.00	0.79 (0.59, 1.03; p=0.082)		1.00	0.75 (0.56, 0.97; p=0.024)
URTI						
Antibiotics Prescribed	Crude percentage	292/940 (31.06%)	265/923 (28.71%)		289/907 (31.86%)	268/956 (28.03%)
	Basic risk ratio	1.00	0.94 (0.81, 1.08; p=0.373)		1.00	0.94 (0.81, 1.09; p=0.445)
	Adjusted risk ratio	1.00	0.81 (0.57, 1.10; p=0.188)		1.00	0.83 (0.59, 1.12; p=0.232)

570

571

572
573
574

LRTI/URTI Individual group analysis

LRTI	Control	CRP	Enhanced communication	Combined
Crude percentage antibiotic prescribed	378/642 (58.88%)	295/575 (51.30%)	294/651 (45.16%)	433/849 (51.00%)
Basic risk ratio	1.00	0.86 (0.59, 1.13; p=0.333)	0.75 (0.50, 1.01; p=0.064)	0.72 (0.49, 0.98; p=0.036)
Adjusted risk ratio	1.00	0.76 (0.47, 1.06; p=0.112)	0.71 (0.45, 0.99; p=0.046)	0.59 (0.36, 0.86; p=0.003)
URTI	Control	CRP	Enhanced communication	Combined
Crude percentage antibiotic prescribed	180/486 (37.04%)	109/421 (25.89%)	112/454 (24.67%)	156/502 (31.08%)
Basic risk ratio	1.00	0.74 (0.48, 1.08; p=0.104)	0.75 (0.49, 1.08; p=0.138)	0.80 (0.53, 1.14; p=0.240)
Adjusted risk ratio	1.00	0.58 (0.36, 0.92; p=0.018)	0.60 (0.37, 0.94; p=0.023)	0.67 (0.42, 1.01; p=0.053)

575
576

